This product is the first immunostimulant that effectively reduces mortality and lung lesions by enhancing the animal’s own immune system to help fight this infectious disease, potentially reducing the need for antibiotics.

The company formulated the immunostimulant with a unique composition that rapidly triggers the animal’s innate immune system, preparing it to better fight infection when challenged by Mannheimia haemolytica.

This product is not an antibiotic nor is it a vaccine. Antibiotics are used for treatment by selectively targeting specific bacterial pathogens. Vaccines are used for preventing disease by triggering a specific immune response only to those pathogens included in the vaccine. DNA immunostimulants are a new way to fight BRD by jumpstarting the innate immune system and enhancing the body’s own ability to respond quickly and effectively.

The product has been shown to counter the multi-factorial complex known as BRD associated with Mannheimia haemolytica for cattle 4 months old or older, when administered at the time of, or within 24 hours after, a perceived stressful event. In a clinical study, the product significantly reduced mortality and lung lesions in comparison with cattle that did not receive it.

“Zelnate provides a new non-antibiotic option that producers can use to complement current approaches for treating BRD,” says Jim Sears, senior technical services veterinarian for the company.

For more information, visit the Zelnate website.  

—From Bayer HealthCare news release

References omitted but are available upon request. Click here to email an editor.